About Gilead
Gilead is a publicly listed company based in Foster City (United States) founded in 1987. Developer of medicines to treat HIVAIDS, liver diseases, cancer others. The company has 17,600 employees. Gilead has completed 21 acquisitions, including Arcellx, Arresto BioSciences and CGI Pharmaceuticals. Its website gilead.com draws about 577 thousand monthly visits. Its Indian entity Gilead Sciences India Private Limited reported revenue of ₹11.00 Cr. Gilead offers products and services including Antiviral Medicines, Oncology Drugs, and Inflammation Treatments. Its focus areas include Diversified Pharmaceuticals and Drugs. Its competitors include Roivant Sciences, AbbVie and Lilly; 1 of its 3 listed competitors has raised funding.
Company details
Founded in 1987 and headquartered in Foster City, United States, Gilead operates as a research-based biopharmaceutical company. Innovative medicines are discovered, developed, and commercialized to address unmet medical needs in HIVAIDS, liver diseases, and cancer. Key developments include the Lenacapavir capsid inhibitor for HIV and the Selgantolimod TLR-8 agonist for HBV. In 2022, annual revenues of 27.28 billion and net profit of 4.59 billion were recorded.
- Indian entity revenue₹11.00 Cr
FY 2024 · +2% YoY
- Indian entity net profit₹1.07 Cr
FY 2024 · 10% margin
- Indian entity EBITDA₹1.44 Cr
FY 2024 · 13% margin
- Latest Funding Round$290K (USD), Post-IPO
Jan 2025
- InvestorsWealth Enhancement
& 8 more
- Employee Count17,600
- Investments & AcquisitionsArcellx
& 20 more
Associated legal entities of Gilead
Gilead operates through Gilead Sciences India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Gilead Sciences India Private Limited CIN U74120DL2014FTC308398 | Active | 26 Jul 2014 | New Delhi, Delhi | ₹11.0 Cr | 4 | View details |
Products & Services of Gilead
Gilead offers a comprehensive portfolio of products and services, including Antiviral Medicines, Oncology Drugs, and Inflammation Treatments.
Treatments for HIV, viral hepatitis, and emerging viruses
Therapies for cancer and related conditions
Medicines for inflammatory diseases and disorders
Apps and channels of Gilead
Gilead publishes 2 mobile apps with over 100 downloads; its YouTube channel Gilead Sciences has 5.9K subscribers and 30 videos.
Videos from Gilead
The most watched videos on Gilead's YouTube channel, Gilead Sciences (5.9K subscribers). Click a video to play it here.
More on Gilead Sciences.
Funding Insights of Gilead
- Total Rounds 5
- Last Round Post-IPO — $290,000
- First Round $2.5B
(Jul 2010)
- Investors Count 8
All 5 funding rounds of Gilead with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $290,000 | Post-IPO | – | – | |
| Jul 2020 | $82.03M | Grant | – | – | |
| Jan 2020 | Grant | – | – | ||
| Apr 2017 | $1.21M | Post-IPO | – | – | |
| Jul 2010 | $2.5B | Post-IPO | – | – | – |
9 investors in total: 9 institutional.
Investors in Gilead
Gilead has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Wealth Enhancement, DriveWealth and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors including healthcare are invested in by IFM Investors. | ifminvestors.com | Melbourne, Australia | ||
Cloud-based API solutions for embedded investing are provided online. | 2012 | drivewealth.com | Chatham, United States | |
Investment management services are offered by Bellevue in Switzerland. | 1993 | bellevue.ch | Zurich, Switzerland | |
Personalized investment solutions are provided for taxable investors. | quantinno.com | New York, United States | ||
Provides wealth planning, investment management, and advisory services to affluent clients and businesses. | 2000 | ironfinancial.com | United States | |
Retirement planning and wealth management services are provided. | 1996 | yourwealth.com | Atlanta, United States | |
Diversified investment management services are provided to clients. | 1997 | wealthenhancement.com | Minneapolis, United States | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Long, short, event-driven, and multiple strategies are employed by Citadel. | 1990 | citadel.com | Chicago, United States |
Investor details for Gilead
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Gilead Sciences India Private Limited (Gilead)
Gilead Sciences India Private Limited is the primary company behind Gilead. The board of Gilead Sciences India Private Limited currently have 4 directors; the longest-serving is Rahul Shivram Bargaje, appointed in 2018. 12 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rahul Shivram Bargaje DIN 08028356 | Director | 10 Jan 2018 | 8 yrs 9 mo | Gilead Sciences India Private Limited |
| Hans York-Julian Stucker DIN 10255037 | Director | 08 Aug 2023 | 3 yrs 2 mo | Gilead Sciences India Private Limited |
| Janet Elizabeth Dorling DIN 10255082 | Director | 08 Aug 2023 | 3 yrs 2 mo | Gilead Sciences India Private Limited |
| Sebastiano Cicognani DIN 11306405 | Additional Director | 01 Oct 2025 | 1 yr | Gilead Sciences India Private Limited |
People of Gilead
886 people are tracked at Gilead (559 in leadership, 9 in board & advisors, 318 in team); the tracked headcount is 17,600.
| Name | Role | Group |
|---|---|---|
Ambika Rana | Associate Director, Data Science | Leadership |
Rebecca Gledhill | Senior Manager, People Partner EMEA | Leadership |
Rie Devert | Senior Director, Patient Safety | Leadership |
Herman Wong | Director, Global Medical Information | Leadership |
Erin Burkhart | Senior Vice President, Controller & Chief Accounting Officer | Leadership |
Cesar Garcia Gonzalez | Business Analytics Associate Director | Leadership |
Jaymin Mehta | Vice President, Global Commercial Head Of Liver, Inflammation, Covid-19, And Established Products | Leadership |
Lucy Guest | Associate Director, Regulatory Operations | Leadership |
Rajesh Ravikumar | Associate Director, Integrated Insights And Analytics | Leadership |
Vimal Unewal Supply Chain Leader | Director, Trade Operations Uk/ire | Leadership |
Joni Kane | Director | Leadership |
Henriette Burghoorn | Associate Director, Market Access | Leadership |
Christine T. | Associate Director, Disability Inclusion & Strategic Projects | Leadership |
J.c. Andry | Director, Medical Excellence - Global Medical Strategy & Operations | Leadership |
Jonathan Israel | Associate Director, Business Analytics & Commercial Excellence | Leadership |
Kristen Pela | Head Of Learning, Communications & Knowledge Management | Leadership |
Simon L. | Director, Strategic Projects, CEO Office | Leadership |
Anupam Talapatra | Global Director Of Regulatory Affairs (precision Medicine), Previously IVD Quality Business Partner | Leadership |
Kerstin Schmidt | Senior Director, Global Medical Affairs, Oncology, Genitourinary Cancers | Leadership |
Qiang Liu | Executive Director | Leadership |
866 more people are available in the full profile.
Complete people profiles for Gilead
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Gilead
Gilead is a publicly listed company on the NASDAQ with ticker symbol GILD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Oct 2017
- Listed onEuronext: 1GILD
- Listed entityGilead Sciences, Inc.
- Exchange sectorHealth technology
- ISINUS3755581036
- Share price$147.92 (-1.67% on the day) · 2026-10-13
- Market capitalisation$183.41B
- Price to earnings19.3
- EPS (diluted, trailing year)$-2.66
- Dividend yield2.2%
- Volume (last session)5,558,196
Financials of Gilead
Figures of Gilead Sciences India Private Limited, the primary company behind Gilead, for FY 2024. Revenue was ₹11.00 Cr (+2% year on year). Net profit was ₹1.07 Cr (10% margin). EBITDA was ₹1.44 Cr (13% margin). Revenue has grown at a compounded annual rate of +33% over three years and +8% over five years.
- ₹11.00 CrRevenue · FY 2024 · +2% YoY
- ₹1.07 CrNet profit · 10% margin
- ₹1.44 CrEBITDA · 13% margin
- ₹5 LakhPaid-up capital
- +33%Revenue CAGR, 3 years
- +8%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $29.45B | $8.51B | $14.58B |
| 2024 | $28.73B | $480.0M | $13.43B |
| 2023 | $27.06B | $5.67B | $12.44B |
| 2022 | $27.09B | $4.59B | $12.86B |
| 2021 | $27.37B | $6.22B | $12.25B |
Balance sheet, profit and loss, cash flow and ratios of Gilead Sciences India Private Limited are on its company page.
Detailed financial statements for Gilead
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gilead
Gilead has strategically engaged in corporate development activities, having acquired 21 companies. Notable acquisitions include Arcellx, Arresto BioSciences and CGI Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Antibody-drug conjugates for cancer treatment are developed using proprietary platforms. | tubulis.com | Berlin, Germany | 2015 | Apr 2026 | $5B | |
Therapeutics for chronic immune-mediated diseases are developed by Ouro Medicines. | ouromedicines.com | San Francisco, United States | 2024 | Mar 2026 | •••• | |
T cell-mediated therapies are developed for cancer and autoimmune diseases. | arcellx.com | Gaithersburg, United States | 2014 | Feb 2026 | $7.8B | |
Developer of therapeutics for liver and other chronic diseases | cymabay.com | Hayward, United States | 1991 | Feb 2024 | $4.3B | |
Small-molecule therapeutics for immuno-oncology diseases are developed. | xinthera.com | San Diego, United States | 2021 | May 2023 | •••• | |
Developer of therapeutics for auto-immune diseases | mirobio.com | Oxford, United Kingdom | 2019 | Aug 2022 | $405M | |
Surface peptide fragment for treating Hepatitis B and D infections | myr-pharma.com | Borgwedel, Germany | 2010 | Dec 2020 | $1.39B | |
Developer of antibodies and antibody-drug conjugates for the treatment of cancer and autoimmune diseases | immunomedics.com | Morris Plains, United States | 1982 | Sep 2020 | •••• | |
Therapies for diverse diseases including oncology are developed. | fortyseveninc.com | Palo Alto, United States | 2015 | Mar 2020 | $4.9B | |
CAR T-cell immunotherapies for cancer and diseases are developed. | celldesignlabs.com | San Francisco, United States | 2016 | Dec 2017 | $567M |
Complete acquisition details for Gilead
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Gilead
15 dated milestones of Gilead across 39 years, from founding to its latest funding, stage changes and deals.
- Founded Gilead is founded.
- Funding First funding round of $2.5B.
- Exit Acquired by Citadel.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Cell Design Labs.
- Acquisition Acquires Forty Seven.
- Acquisition Acquires Immunomedics.
- Acquisition Acquires MYR Pharma.
- Acquisition Acquires MiroBio.
- Acquisition Acquires XinThera.
- Acquisition Acquires CymaBay Therapeutics.
- Funding Latest funding round, Post-IPO, of $290K.
- Acquisition Acquires Arcellx.
- Acquisition Acquires Ouro Medicines.
- Acquisition Acquires Tubulis.
Competitors of Gilead
Gilead has 3 listed competitors in our database, 1 of them funded. They include Roivant Sciences, AbbVie and Lilly.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| abbvie.com | 2012 | Chicago, United States | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | ||
| lilly.com | 1876 | United States | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. |
Detailed competitors of Gilead
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Gilead
The website of Gilead (gilead.com) receives about 576.5K visits a month and ranks #103,109 among all websites worldwide, #2,979 in Health.
- Monthly visits576.5K
▲ 8.2% vs previous month
- Unique visitors115.9K
per month
- Global rank#103,109
among all websites
- Category rank#2,979
Health · Health
- Bounce rate30%
- Pages per visit3.7
- Average visit2 min 40 sec
- DevicesDesktop 79% · Mobile 21%
Websites whose visitors overlap most with Gilead. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
biogenidec.com | biogenidec.com | 100% | – | ||
| bms.com | 98% | 809.8K | #67,210 | View details | |
gileadconnect-my.sharepoint.com | gileadconnect-my.sharepoint.com | 96% | – | ||
| gsk.com | 95% | 1.3M | #56,834 | View details | |
| lilly.com | 92% | 4.9M | #13,252 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Gilead
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Gilead (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gilead
Complete news archive for Gilead
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gilead
Gilead was founded in 1987 and raised its 1st funding round 23 years after it was founded.
Gilead is headquartered in Foster City, United States. It is registered at Foster City, California, United States.
Gilead has 17,600 employees.
The primary company behind Gilead, Gilead Sciences India Private Limited, reported revenue of ₹11.00 Cr for FY 2024, up 2% year on year.
Founded in 1987 and headquartered in Foster City, United States, Gilead operates as a research-based biopharmaceutical company. Innovative medicines are discovered, developed, and commercialized to address unmet medical needs in HIVAIDS, liver diseases, and cancer. Key developments include the Lenacapavir capsid inhibitor for HIV and the Selgantolimod TLR-8 agonist for HBV. In 2022, annual revenues of 27.28 billion and net profit of 4.59 billion were recorded.
Gilead's top competitors include Roivant Sciences, AbbVie and Lilly.
Gilead offers Antiviral Medicines, Oncology Drugs, and Inflammation Treatments.
Yes, Gilead is publicly traded on NASDAQ under the ticker symbol GILD.
Gilead has made 21 acquisitions, including Arcellx, Arresto BioSciences, and CGI Pharmaceuticals.
Gilead has 9 investors. Key investors include Wealth Enhancement, DriveWealth, Citadel, Bellevue, and European Union.
Gilead operates through Gilead Sciences India Private Limited.
Yes. Gilead was acquired by Citadel in October 2016.